Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

被引：0

作者：

Jesper van Breeschoten

Michel W. J. M. Wouters

Doranne L. Hilarius

John B. Haanen

Christian U. Blank

Maureen J. B. Aarts

Franchette W. P. J. van den Berkmortel

Jan-Willem B. de Groot

Geke A. P. Hospers

Ellen Kapiteijn

Djura Piersma

Roos S. van Rijn

Karijn P. M. Suijkerbuijk

Willeke A. M. Blokx

Bert-Jan J. ten Tije

Astrid A. M. van der Veldt

Art Vreugdenhil

Marye J. Boers-Sonderen

Alfonsus J. M. van den Eertwegh

机构：

[1] Dutch Institute for Clinical Auditing,Department of Medical Oncology

[2] Amsterdam UMC,Department of Surgical Oncology

[3] VU University Medical Center,Department of Pharmacy

[4] Cancer Center Amsterdam,Department of Medical Oncology and Immunology

[5] Netherlands Cancer Institute,Department of Molecular Oncology & Immunology

[6] Rode Kruis Ziekenhuis,Department of Medical Oncology

[7] Netherlands Cancer Institute,Department of Medical Oncology

[8] Netherlands Cancer Institute,Department of Medical Oncology

[9] Maastricht University Medical Centre,Department of Medical Oncology

[10] Zuyderland Medical Centre Sittard,Department of Internal Medicine

[11] Isala Oncology Center,Department of Internal Medicine

[12] Isala,Department of Medical Oncology

[13] University Medical Centre Groningen,Department of Pathology, Division of Laboratories

[14] Leiden University Medical Centre,Department of Internal Medicine

[15] Medisch Spectrum Twente,Departments of Medical Oncology and Radiology & Nuclear Medicine

[16] Medical Centre Leeuwarden,Department of Internal Medicine

[17] University Medical Centre Utrecht,Department of Medical Oncology

[18] Pharmacy and Biomedical Genetics,undefined

[19] University Medical Center Utrecht. Heidelberglaan 100,undefined

[20] Amphia Hospital,undefined

[21] Erasmus Medical Centre,undefined

[22] Maxima Medical Centre,undefined

[23] Radboud University Medical Centre,undefined

来源：

British Journal of Cancer | 2022年 / 126卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1362 / 1362

共 42 条

[31] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Dummer, Reinhard
Welti, Michele
Ramelyte, Egle
JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
[32] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Reinhard Dummer
Michèle Welti
Egle Ramelyte
Journal of Translational Medicine, 21
[33] Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer
Cheng, Rihua
Zhou, Zhen
Liu, Qiao
CANCER MEDICINE, 2023, 12 (06): : 7389 - 7397
[34] Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey
Fabre, Marie
Lamoureux, Anouck
Meunier, Laurent
Samaran, Quentin
Lesage, Candice
Girard, Celine
Du Thanh, Aurelie
Moulis, Lionel
Dereure, Olivier
MELANOMA RESEARCH, 2024, 34 (03) : 241 - 247
[35] The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i
Dummer, Reinhard
Schadendorf, Dirk
Nathan, Paul
Tawbi, Hussein
Robert, Caroline
Ascierto, Paolo A.
Ribas, Antoni
Lebbe, Celeste
Mandala, Mario
Yamazaki, Naoya
Richtig, Erika
Miller, Wilson H.
Gasal, Eduard
Kaper, Mathilde
Brase, Jan C.
Mookerjee, Bijoyesh
Long, Georgina V.
CANCER RESEARCH, 2018, 78 (13)
[36] The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I
Long, Georgina V.
Lebbe, Celeste
Atkinson, Victoria
Mandala, Mario
Nathan, Paul D.
Arance, Ana
Richtig, Erika
Yamazaki, Naoya
Robert, Caroline
Schadendorf, Dirk
Tawbi, Hussein Abdul-Hassan
Ascierto, Paolo Antonio
Ribas, Antoni
Flaherty, Keith
Lee, Dung-Yang
Masood, Aisha
Gasal, Eduard
Dummer, Reinhard
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
[37] Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis
Zhong, Qiaofeng
Zhang, Longfeng
Wu, Lin
Zhao, Jun
Sun, Jianguo
Fang, Yong
Zhou, Jin
Chu, Qian
Shen, Yihong
Yang, Zhenzhou
Chen, Lijin
Huang, Meijuan
Lin, Xiaoyan
Liu, Zhenhua
Shen, Peng
Wang, Zhijie
Wang, Xin
Wang, Huijuan
Han, Chengbo
Liu, Anwen
Zhang, Hongmei
Ye, Feng
Gao, Wen
Wu, Fang
Song, Zhengbo
Chen, Shengchi
Zhou, Chengzhi
Huang, Dingzhi
Zhang, Qiuyu
Zheng, Xinlong
Zheng, Xiaobin
Miao, Qian
Jiang, Kan
Zou, Zihua
Xu, Yiquan
Wu, Shiwen
Wang, Haibo
Hong, Yaping
Lu, Tao
Li, Chao
Huang, Cheng
Chen, Chuanben
Lin, Gen
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
[38] Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress
Qin, S.
Finn, R.
Kudo, M.
Meyer, T.
Vogel, A.
Ducreux, M.
Macarulla, T.
Tomasello, G.
Boisserie, F.
Hou, J.
Li, C.
Song, J.
Zhu, A.
ANNALS OF ONCOLOGY, 2018, 29
[39] A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.
Qin, Shukui
Finn, Richard S.
Kudo, Masatoshi
Meyer, Tim
Vogel, Arndt
Ducreux, Michel
Mercade, Teresa Macarulla
Tomasello, Gianluca
Boisserie, Frederic
Hou, Jeannie
Li, Cindy
Song, James
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] Preliminary findings from part 1 of COMBI-i: A phase III study of anti-PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
Dummer, Reinhard
Fernandez, Ana Maria Arance
Hansson, Johan
Larkin, James M. G.
Long, Georgina V.
Gasal, Eduard
Kaper, Mathilde
Upalawanna, Allison
Mookerjee, Bijoyesh
Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)

← 1 2 3 4 5 →